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n-3 Fatty Acid Ethyl Ester Administration to
Healthy Subjects and to Hypertriglyceridemic
Patients Reduces Tissue Factor Activity
in Adherent Monocytes
Elena Tremoli, Sonia Eligini, Susanna Colli, Paola Maderna, Patrizia Rise, Franco Pazzucconi,
Franca Marangoni, Cesare R. Sirtori, Claudio Galli
Abstract n-3 Fatty acids are known to influence several
functions of monocytes, including adhesion, cytokine synthesis,
and superoxide generation. Monocytes express tissue factor, a
membrane-bound grycoprotein, that acts as a catalyst in the
coagulation cascade. In this study we evaluated the effects of
administration of n-3 fatty acid ethyl esters to healthy volun-
teers and to hypertriglyceridemic patients on tissue factor
activity (TF activity) in adherent monocytes. n-3 Fatty acids
containing 75% eicosapentaenoic acid (EPA) and docosa-
hexaenoic acid (DHA) (ratio of EPA to DHA, 1.34) were
administered (3 g/d) to normal volunteers for 18 weeks. In
addition, the effects of this treatment were evaluated in 30
hypertriglyceridemic patients for 24 weeks by using a double-
blind, placebo-controlled study. TF activity in adherent mono-
cytes was evaluated with a one-stage clotting assay. Plasma and
monocyte fatty acid compositions were determined by gas-
liquid chromatography. In healthy volunteers, n-3 fatty acids
significantly reduced TF activity in adherent monocytes either
Epidemiological and interventional studies suggestthat consumption of fish or fish oil containingelevated levels of n-3 poh/unsaturated fatty ac-
ids confers protection against ischemic heart disease.1-2
In addition, it has been shown that n-3 fatty acids exert
beneficial effects in humans and animals with atheroscle-
rotic disease.34 Some of these effects may be attributed
to the activity of n-3 fatty acids on platelet activation, as
well as on changes in the behavior of cells of the vessel
wall.36 Moreover, n-3 fatty acids inhibit several functions
of monocytes, ie, adhesion,7 chemotaxis,8 cytokine syn-
thesis,9 leukotriene generation,10 and expression of
mRNA for platelet-derived growth factor.11
Tissue factor (TF) is a membrane-bound glycoprotein
that functions in the extrinsic pathway of blood coagu-
lation by acting as a cofactor for factor VII.12-13 TF binds
the plasma serine protease, factor Vila; the resulting
factor VIIa-TF complex acts as a catalyst for conversion
of factors IX to IXa and X to Xa, leading to the
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in the unstimulated condition or after exposure to endotoxin.
The inhibitory effect was observed after 12 weeks of treatment
and was more pronounced after 18 weeks (>70%, P<.001
versus baseline). Concomitantly, levels of EPA and DHA
increased in plasma and monocyte lipids. Interestingly, after
stopping treatment, monocyte TF activity remained inhibited
for at least 14 weeks. Treatment with n-3 fatty acids for 24
weeks also resulted in a significant reduction of TF activity in
adherent monocytes from hypertriglyceridemic patients
(—31% and —40% in unstimulated and endotoxin-stimulated
cells; P<.05 versus baseline). The described effect of n-3 fatty
acids on TF activity in monocytes from healthy subjects and
hypertriglycerideraic patients represents a novel mechanism by
which these fatty acids may exert their antithrombotic activity.
(ArUriosder Thromb. 1994;14:1600-1608.)
Key Words • eicosapentaenoic acid • docosahexaenoic
acid • procoagulant activity • thrombosis
formation of thrombin.14 TF activity has been identified
in several different tissues and, among blood cells, in
monocytes.15 Monocyte TF activity has been shown to
be increased in various animal models after endotoxin
shock.16'17 In addition, elevated levels of TF activity
have been reported during extracorporeal circulation in
patients undergoing aortocoronary bypass,18 possibly
due to monocyte activation consequent to surgical ma-
neuvers and during the outburst of unstable angina, as a
result of lymphocyte activation from yet-undiscovered
factor(s).19 Moreover, TF has been found in the matrix
of necrotic cores of atherosclerotic plaques.20
Factor VII coagulant has been described to correlate
with the risk of future coronary events, and serum
triglycerides have been shown to be associated with
factor VII coagulant levels.21-22 Factor VII circulates in
the plasma as an inert precursor (zymogen) that, during
clotting, is converted to the activated form (factor Vila)
by cleavage of a single peptide bond. Factor Vila is
inactive unless it binds to its essential cofactor, TF, and
it has been proposed that low levels of factor Vila serve
as a primer, through the formation of a binary complex
with TF, in initiating the clotting cascade.23
Recently it has been demonstrated that dietary ad-
ministration of fish oil to nonhuman primates impairs
TF expression by endotoxin-stimulated mononuclear
cells.24 In this study we demonstrate that supplementa-
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tion with n-3 fatty acids enriched in eicosapentaenoic
(EPA) and docosahexaenoic (DHA) acids to healthy
volunteers and to hypertriglyceridemic patients reduces
TF activity generation in adherent monocytes in the
unstimulated condition as well as after stimulation with
endotoxin.
Methods
Materials
Plastic culture dishes were from Costar; phosphate-buffered
saline (PBS) and RPMI-1640 were from Flow; bovine serum
albumin was from Sigma Chemical Co; Ficoll-Paque was from
Pharmacia; penicillin, streptomycin, and amphotericin B (Fun-
gizone) were from GIBCO; endotoxin W from Escherichia coli
0111:B4 was from DIFCO; methanolic HC1 and gas-liquid
chromatography columns were from Supelco; human placental
thromboplastin was from Behring; and monoclonal antibody
against TF activity was from American Diagnostica.
The capsules of n-3 fatty acids (1 g each) containing 75%
EPA plus DHA (430 mg EPA and 320 mg DHA; EPA to DHA
ratio, 1.34) and 25% other n=3 fatty acids and the olive oil
capsules (1 g each of olive oil, containing 78% oleic acid) were
from Pharmacia-Farmitalia Carlo Erba srl.
Subjects and Patients
A preliminary study was carried out in eight healthy volun-
teers (4 men and 4 women; age range, 23 to 39 years) selected
from the staff attending the E. Grossi Paoletti Center for the
Study of Metabolic Diseases (Niguarda Hospital, Milan, Italy).
The subjects were disease-free and refrained from taking any
medication during the course of the study. After the prelimi-
nary study was completed, a double-blind, placebo-controlled
study was carried out in hypertriglyceridemic patients. Thirty
hypertriglyceridemic patients were selected at the E. Grossi
Paoletti Center. Patient selection was based on diagnosis of
type IV hyperlipoproteinemia according to World Health
Organization (WHO) criteria.23 None of the patients had
clinical signs of atherosclerotic disease, nor were they hyper-
tensive or diabetic. Mean plasma triglyceride level was
3.72±0.42 and 4.20±0.45 mmol/L in patients assigned to n-3
fatty acid and olive oil treatments, respectively. Mean total
cholesterol levels were 6.26±0.24 and 5.78±0.27 mmol/L,
respectively, for the two groups. None of the patients was
taking hormonal therapies or other drugs known to interfere
with lipid or coagulation parameters.
During these studies healthy subjects and patients were
asked to continue their usual diet and to refrain from consum-
ing foods rich in n-3 fatty acids, eg, salmon, herring, and tuna
fish. The diet of healthy subjects contained 40% fat: 14%
saturated, 22% monounsaturated, and 3% to 4% poh/unsatu-
rated, with a poh/unsaturated to saturated fat ratio of 0.3.
From at least 1 month before the beginning of the study, the
patients were on a low lipid/carbohydrate diet according to
established guidelines in Italy: 40% fat, with a polyunsaturated
to saturated fat ratio >1.8, 38% to 40% carbohydrate, and
20% protein.26 From the actual lipid contents and fatty acid
composition of the diets, it was calculated that dairy consump-
tion of EPA and DHA by patients and control subjects was
<50mg(DHA>>EPA).
The studies were performed according to the Declaration of
Helsinki. The project was approved by the Ethics Committee
of the E. Grossi Paoletti Center. All participants were care-
fully informed of the end points of the study. Informed consent
was obtained from all subjects entering the study.
Study Design
In the preliminary study, healthy subjects were administered
3 g/d n-3 fatty acids (three capsules, 1 g each) for 18 weeks.
Blood sampling was performed at weeks 0 (baseline), 6, 12,
and 18 during treatment and 14 weeks after treatment with-
drawal. At these times plasma lipids, monocyte TF activity,
and plasma and monocyte fatty acid composition were deter-
mined. At week 14 after treatment withdrawal, TF activity was
also determined in monocytes isolated from a group (n=6) of
normal donors not exposed to treatment with n-3 fatty acids
and who were matched for age and sex to the study subjects.
After the preliminary study was completed, a double-blind,
placebo-controlled study was carried out in hypertriglyceri-
demic patients. Hypertriglyceridemic patients were randomly
assigned to receive either 3 g/d n-3 fatty acids or 3 g/d olive oil
for 24 weeks. Blood was drawn at time 0 (baseline) and at 12,
18, and 24 weeks after starting the treatments for determina-
tion of plasma fatty acid composition and monocyte TF
activity. Before and at the end of treatment, hematocrit;
erythrocyte, leukocyte, and platelet counts; and hepatic and
renal function tests were performed.
Monocyte Isolation and Stimulation
All procedures for monocyte isolation were performed
under sterile conditions. Blood, anticoagulated with 3.8%
sodium citrate (9:1, vol/vol), was centrifuged at 150g for 18
minutes to obtain platelet-rich plasma, which was discarded.
The residue was processed for mononuclear cell isolation by
adding an equal volume of PBS containing 0.5% bovine serum
albumin and 0.1% glucose. Mononuclear cells were separated
by centrifugation on Ficoll-Paque. For monocyte purification,
mononuclear cells were washed twice with PBS containing 5
mmol/L EDTA to eliminate platelet contamination and once
with PBS containing 0.5% bovine serum albumin. Cells were
then resuspended in RPMI-1640 plus 50 U/mL penicillin, 50
fig/mL streptomycin, 0.125 fig/mL amphotericin B (Fungi-
zone), and 10% autologous serum. Cells were placed in 16-mm
multiwell tissue-culture plates at 2x 10' cells per well and kept
at 37°C in a 5% CO2 humid atmosphere for 2 hours. Super-
natants containing nonadherent cells were removed, and ad-
herent monocytes were washed twice with prewarmed RPMI-
1640. The purity of monocyte preparations was >90%, as
defined by cytochemical reactivity for onaphthyl acetate
esterase.27 Cell viability was determined by trypan blue dye
exclusion. For fatty acid analyses, adherent monocytes were
gentry scraped off and subjected to osmotic lysis with distilled
water, and the final pellets were stored at —80°C until assayed.
For TF activity determination, adherent monocytes were
incubated for 4 hours at 37°C in a 5% CO2 humid atmosphere
in the absence or presence of 10 ng/mL endotoxin. At the end
of incubation, cells were scraped off and subjected to three
cycles of freezing and thawing. Each well was then examined
by microscopy to ensure that most of the cells had been
scraped from the plates. Monocyte TF activity was determined
in cell extracts as described below.
In preliminary experiments, adherent cells were detached
from wells by incubation with PBS containing 5 mmol/L
EDTA (pH 7.4) and counted by phase-contrast microscopy,
and cell protein content was evaluated in the same samples
with the Bio-Rad protein assay.28 A linear relation between
cell count and protein concentration in cell extracts was found
(r=l). Therefore, to minimize intrasubject and intersubject
variations in the number of adherent cells, monocyte TF
activity was determined in cell extracts and expressed as units
of TF activity per microgram of protein.
Plasma Lipids
Serum total cholesterol and trigtycerides were determined
by enzymatic methods.29-30 Lipid determinations were stan-
dardized within the WHO Quality Control Program, the
coefficients of variation for total cholesterol and trigrycerides
being 1.5% and 2.3%, respectively.
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Fatty Acid Analyses
For measurement of plasma fatty acids, blood was collected
in EDTA (1 mg/mL of blood) and centrifuged for 20 minutes
at 800g. The plasma was removed and frozen at -80°C until
analyzed. Lipids were extracted from plasma by the stepwise
addition (to 1 volume of plasma) of 2 volumes distilled water,
4 mL methanol, and 8 mL chloroform containing 5 /ig/mL of
the antioxidant butylated hydroxytoluene. After phase sepa-
ration at low temperature, the aqueous phase was collected
and, after solvent evaporation, redissorved in chloroform/
methanol, 2:1, vol Axil. Lipids from monocyte membranes were
extracted with chloroform/methanol (2:1, vol/vol) containing 5
/xg/mL butylated hydroxytoluene.31-32 The contents of extracts
were determined from aliquots by microgravimetry after sol-
vent evaporation. Total phospholipids were isolated from lipid
extracts by thin-layer chromatography with hexane/diethyl
ether/acetic acid, 80:20:1, vol/vol/vol, as developing agents.
The zones containing total phospholipids were scraped off.
Fatty acid methyl esters were prepared by transmethylation
with methanolic HC1. The methyl esters were separated by
gas-liquid chromatography on capillary columns (Supelcowax
10: fused silica, 30 m, 0.32-mm internal diameter, 0.25-mm
film thickness) at a programmed temperature (140°C to 210°C
in 2.5°C/min increments). Quantification of fatty acids was
carried out by the use of the internal standard nonadecane and
calibration curves obtained with reference compounds.
TF Activity Determination
Total cellular content of TF activity was determined by a
one-stage clotting assay on disrupted monocytes.33 The assay
mixture contained 0.1 raL cell lysates; 0.1 mL citrated, pooled,
normal plasma; and 0.1 mL of 25 mmol/L CaCl2. Clotting times
were determined at 37°C and results were expressed in arbi-
trary units by comparison with a standard curve of clotting
times, which were obtained by serial dilutions of a preparation
of human placental thromboplastin to which an arbitrary value
of 2000 U was assigned. Assays performed with plasma from
donors who were congenitally deficient in factor VII consis-
tently demonstrated no TF activity. TF activity was expressed
as units per microgram of protein. The specificity of this assay
for TF activity was shown by preincubation of cells with an
inhibitory monoclonal antibody against TF that blocked the
activity by >90%.
Statistical Analysis
The results are presented as mean±SEM. Two-way
ANOVA for paired data was used to evaluate the effect of n-3
fatty acids in healthy subjects. Two-way ANOVA with a
two-factor mixed design (split-plot design) was used to com-
pare treatment conditions in hypertriglyceridemic patients.
Statistical significance was analyzed by Tuke/s test for multi-
ple comparisons; probability values greater than 0.05 were not
considered significant.
Results
All subjects (healthy volunteers and hypertriglyceri-
demic patients) completed the study without major
adverse effects, with the exception of one hypertriglyc-
eridemic patient who left the study because of gastro-
intestinal disturbances. In both volunteers and patients,
body weight as well as other indices, eg, pulse and blood
pressure, did not change during the study. In addition,
there were no alterations in major hematologic and
biochemical parameters with the exception of plasma
lipids.
Treatment with n-3 fatty acids reduced trigh/ceride
levels in healthy subjects (from 0.88±0.10 mmol/L at
baseline to 0.69±0.11 mmol/L after 18 weeks of treat-
ment; NS) and in hypertriglyceridemic patients (from
3.72±0.42 mmol/L at baseline to 2.2±0.13 and 2.5+0.12
mmol/L at 18 and 24 weeks of treatment, respectively;
P<.Q\). No significant change in triglyceride levels was
observed in the olive oil group during treatment
(4.20±0.45 and 3.90±0.29 mmol/L at baseline and at
week 24, respectively; NS). No changes in plasma
cholesterol levels were recorded in normal subjects
during treatment (4.87±0.10 and 4.68±0.16 mmol/L at
baseline and after 18 weeks of n-3 fatty acids, respec-
tively; NS). In hypertriglyceridemic patients, plasma
cholesterol levels tended to increase during the study
(from 5.77±0.27 mmol/L at baseline to 6.29±0.29
mmol/L after 24 weeks for the placebo group [P<.01]
and from 6.27±0.25 mmol/L at baseline to 6.70+0.24
mmol/L after 24 weeks for the n-3 fatty acid group
[Z'<.05]). At 24 weeks, however, no significant differ-
ence was observed in the two treatment groups.
Preliminary Study: Effects of n-3 Fatty Acid
Administration to Healthy Volunteers
In this study, TF activity was determined in adherent
monocytes incubated for 4 hours with medium alone or
with medium containing 10 iig/mL endotoxin. TF activ-
ity, as determined in freshly isolated mononuclear cells
of healthy subjects, was below the detection limit of the
assay (clotting times >7 minutes). As has already been
observed by others,34-35 appreciable amounts of TF
activity are detectable after adherence of monocytes to
tissue-culture plates. A further increase in TF activity
was observed after a 4-hour incubation of adherent cells
with medium alone at 37°C (5% CO2 and a humid
atmosphere).
Before treatment, TF activity as determined in mono-
cytes incubated with medium alone was 7.0 ±1.1 U/^.g
protein (range, 4.0 to 13.9 U/^tg protein, n=8). Incuba-
tion of adherent monocytes with 10 /xg/mL endotoxin
induced an almost 100% increase in monocyte TF
activity compared with that in the unstimulated condi-
tion (13.1±1.8 U/jtg protein; range, 8.7 to 23.2 U/^g
protein, n = 8).
Levels of TF activity in unstimulated, adherent mono-
cytes at baseline and during n-3 fatty acid treatment are
presented in Fig 1A. Six-week treatment with n-3 fatty
acids did not influence TF activity in unstimulated cells,
whereas after 12 weeks, a dramatic reduction in TF
activity was observed. At this time, unstimulated mono-
cytes formed 2.7±0.6 U TF activity per microgram of
protein (range, 0.7 to 4.8 U/iig protein; /><.001 versus
baseline and 6 weeks). A further reduction of monocyte
TF activity compared with values obtained at 12 weeks
was observed after 18 weeks of treatment (mean levels
of TF activity were 2.0±0.12 U/^tg protein; range, 1.3 to
2.3 U///.g protein; P<.001 versus baseline and 6 weeks).
n-3 Fatty acids influenced TF activity in endotoxin-
stimulated monocytes (Fig IB) in a fashion comparable
to that observed in unstimulated cells. Six-week treat-
ment failed to influence TF activity in endotoxin-stim-
ulated cells, and inhibition of TF activity compared with
baseline values was observed only after 12 and 18 weeks
of treatment with n-3 fatty acids. TF activity levels in
endotoxin-stimulated monocytes at 12 and 18 weeks
averaged 5.0±0.4 and 2.6±0.2 U/ttg protein, respec-
tively (P<.001 versus baseline and 6 weeks). After 18
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FIG 1. Bar graphs of tissue factor
activity in monocytes isolated from
healthy subjects during treatment
with n-3 fatty acid ethyl esters (3
g/d) for 18 weeks. Each point rep-
resents the value for each subject
at each time. Values at 12 and 18
weeks (W) were significantly (*) dif-
ferent (P<.001) from values at
baseline and after 6 weeks of treat-
ment in both unstimulated (A) and
endotoxin-stimulated (B) cells.
Mean±SEM values of tissue factor
activity are also shown at each time.
weeks of treatment, not only were the absolute amounts
of TF activity in both unstimulated and stimulated cells
significantly reduced but the percent of stimulation in-
duced by endotoxin was also reduced (30% only versus
100% observed at baseline).
Mean levels of fatty acids in the plasma of healthy
subjects at baseline and during treatment are presented
in Table 1. During treatment the major changes in
plasma fatty acids were related to n-3 polyunsaturates
(20:5, 22:5, and 22:6). EPA (20:5 n-3) and DHA (22:6
n-3) accumulated in plasma lipids after 6 weeks, with
maximal accumulation occurring after 18 weeks of treat-
ment. So far as n-6 fatty acids are concerned, levels of
arachidonic acid (20:4 n-6) in plasma decreased only
slightly during treatment.
Changes in monocyte fatty acid composition essen-
tially reflected those observed in plasma (Table 2), with
marked increases in n-3 fatty acids and a slight reduc-
tion in n-6 fatty acids, a change confined to arachidonic
acid. As a consequence of changes in plasma and
monocyte fatty acids, the 20:4 n-6 to 20:5 n-3 ratio
decreased significantly (Tables 1 and 2).
At 14 weeks after treatment withdrawal, TF activity
was simultaneously evaluated in eight subjects who com-
pleted the study and in six normal donors who had not
been exposed to treatment with n-3 fatty acids. TF
activity levels in unstimulated and endotoxin-stimulated
monocytes from untreated donors were 8.5 ±2.0 and
13.1 ±1.9 V/fig protein, respectively (n=6). These values
are fully comparable with those determined at baseline in
monocytes from healthy volunteers who completed treat-
ment with n-3 fatty acids. In the latter group, in contrast,
TF activity levels measured 14 weeks after treatment
withdrawal were still significantly lower than at baseline
(mean levels of TF activity were 2.0±0.5 and 4.9±0.8
protein for unstimulated and endotoxin-stimulated
TABLE 1. Fatty Acid Composition of Plasma of Healthy Subjects Before, During, and After n-3 Fatty
Acid Administration
Fatty Adds*
16:0
18:0
16:1
18:1
24:1
18:2 n-6
20:3 n-6
20:4 n-6
22:4 n-6
22:5 n-6
20:5 n-3
22:5 n-3
22:6 n-3
20:4n-6/20:5n-3
ratio
0
(Baseline)
21.7±1.0
8.8±0.26
1.2±0.2
21.8±1.7
0.4±0.04
34.5±2.0
1.9±0.15
7.0±0.3
0.16±0.01
0.12±0.01
0.64±0.08
0.31+0.04
1.4±0.1
11.9±1.4
Weeks
6
23.3±1.0
9.7±0.41
1.0±0.1
18.9±1.1t
0.3±0.04
32.4±1.8
1.0±0.1*
6.5±0.8
0.13+0.04
0.08±0.02
3.85±0.4*
0.50±0.06
2.3±0.19t
1.7±0.1*
of Study
12
28.0±1.0+
8.5±0.3
1.2+0.3
17.0±1.&t
0.3±0.09
34.1 ±2.3
0.9±0.1
4.7±0.44:
0.11 ±0.02
0.08±0.02
3.30±0.23t
0.40±0.03
1.9±0.19+
1.4±0.1$
18
24.2±1.2
8.4±0.4
1.3±0.1
18.7±1.1t
1.3±0.2+
29.1 ±0.8
1.0±0.1
6.4±0.3
0.30±0.03
0.17±0.04
4.40±0.37t
0.90±0.07t
3.9±0.26t
1.5±0.1*
After 14 Weeks of
Washout
23.4±0.6
7.4±0.2t
1.5±0.2
20.2±1.5
0.8±0.1
34.0±2.3
1.5±0.1t
6.9±0.3
0.30±0.05
0.30±0.09
0.80±0.13
0.60±0.09+
2.4±0.22t
9.8±1.6
•Values are percentages of total fatty acids and are expressed as mean±SEM. Statistical analysis was performed as described in
"Methods."
tP<.05, *P<.01 versus baseline.
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TABLE 2. Fatty Add Composition of Monocytes In Healthy Subjects Before, During, and After n-3 Fatty
Acid Administration
Fatty Adds*
16:0
18:0
16:1
18:1
24:1
18:2n-6
20:3 n-6
20:4 n-6
22:4 n-6
22:5n-6
20:5 n-3
22:5 n-3
22:6 n-3
20:4n-6/20:5 n-3
ratio
0
(Baseline)
25.9±1.0
20.6±0.9
0.85±0.2
15.9±0.5
1.3±0.2
10.1 ±0.6
1.6±0.22
18.0±0.5
1.8±0.2
0.26±0.05
0.34±0.1
1.4±0.2
1.9±0.26
54.6±7.8
•Values are percentages of total fatty
"Methods."
t/3<.05, tP<.01 versus baseline.
Weeks of
6
24.5±0.85
21.2±0.2
0.45±0.03
15.4±0.5
1.3±0.1
9.8±0.6
1.5±0.08
16.0±0.6
1.0±0.07t
0.17+0.04
1.8±0.17t
3.3±0.2+
3.5±0.22+
9.4±0.8+
acids and are expressed as
Study
12
25.3±1.1
22.5±0.5
1.80±0.5
17.3±0.9
1.3±0.2
8.6±0.6
1.3±0.09
13.3+0.7*
1.3±0.1
0.27±0.03
1.4±0.13+
2.6±0.2$
3.0±0.29+
9.8±1.0±
mean±SEM. Statistical
18
24.7±1.8
22.8±0.4
0.50±0.04
15.7±0.8
1.3±0.1
9.6±1
1.6±0.14
14.5±0.84:
1.2±0.1
0.16±0.02
1.7±0.13±
2.8±0.2t
3.3±0.29±
8.3±0.6+
analysis was
After 14 Weeks
of Washout
25.1 ±1.4
23.2±0.5
0.62±0.05
16.8±0.6
1.2±0.1
7.9±0.4
1.9±0.09
15.8±1.2
1.8±0.1
0.38±0.13
0.58±0.08
1.8±0.1
2.8±0.3t
28.0±3.1$
performed as described in
cells, respectively; P<.Q\ versus baseline and 6 weeks).
Despite treatment withdrawal, absolute amounts of TF
activity were still lower compared with those at baseline;
however, endotoxin stimulation resulted in a consistent
increase of TF activity in monocytes from all subjects
(mean percent increase, 140).
After treatment withdrawal, levels of 20:5 n-3 in
plasma returned toward baseline values (0.8±0.18% of
total fatty acids; not significant versus baseline),
whereas those of 22:6 n-3 remained higher than at
baseline (2.4±0.22% of total fatty acids; P<.01 versus
baseline). A similar trend was also observed in mono-
cytes. Levels of 20:4 n-6 in both plasma and monocytes
were not different from baseline values. The 20:4 n-6 to
20:5 n-3 ratio tended to return toward baseline in
plasma (Table 1), whereas it remained significantly
lower in monocytes (Table 2).
Effects of n-3 Fatty Acid Administration to
Hypertriglyceridemic Patients
The results of the preliminary study carried out in
healthy subjects indicated that n-3 fatty acids profoundly
affected the capacity of monocytes to express TF activity
and that this effect lasted more than 14 weeks after
treatment withdrawal. That study, however, did not
include a placebo group, and this factor could represent
a substantial drawback for its significance. Therefore, a
double-blind, placebo-controlled study with either 3 g/d
n-3 fatty acids or olive oil was carried out in hypertri-
glyceridemic patients. A crossover design was not feasi-
ble because of the prolonged carryover effect of n-3 fatty
acids that we observed; therefore, the study was con-
ducted in two parallel groups of patients randomly
assigned to n-3 fatty acids or olive oil treatment.
At baseline, values of TF activity in adherent mono-
cytes that had been isolated from hypertriglyceridemic
patients were similar to those detected in healthy
subjects (7.3±0.88 and 12.04±1.19 U//*g protein for
unstimulated and endotoxin-stimulated adherent
monocytes, respectively; n = 29). After 18 weeks of
treatment with 3 g/d n-3 fatty acids, TF activity in
unstimulated and endotoxin-stimulated monocytes
was significantly decreased (Fig 2). At this time,
monocytes incubated in medium alone produced only
4.6 U/^tg protein compared with a baseline level of 7.1
U//ig protein (-35%). Similarly, monocytes stimu-
lated with 10 fig endotoxin per milliliter produced 7.1
U/fig protein compared with a baseline level of 12.2
V/fig protein (-41%). These reductions remained
constant for 6 weeks thereafter. Administration of
olive oil for 24 weeks did not significantly influence
monocyte TF activity in the hypertriglyceridemic pa-
tients. When the n-3 fatty acid-treated group was
compared with the olive oil-treated group, it appeared
that TF activity levels in both unstimulated and stim-
ulated monocytes differed significantly at the 14th
week (Fig 2; P<.05).
Compliance with n-3 FA treatment was confirmed by
changes in n-3 and n-6 fatty acids in plasma. Specifi-
cally, 20:5 n-3 in plasma was raised from 0.72±0.18% of
total fatty acids at baseline to 3.7 ±0.26% after 24 weeks
of treatment (P<.00l). Plasma levels of 22:6 n-3 in-
creased from 1.53 ±0.54% to 4.14 ±0.24% of total fatty
acids (Table 3; P<.001). These levels are fully compa-
rable with those recorded in healthy subjects after
administration of the same dose of n-3 fatty acids. So far
as n-6 fatty acids are concerned, 20:4 n-6 levels in
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FIG 2. Une plots of tissue factor activity in
monocytes isolated from hypertriglyceridemlc
patients at baseline (0) and during treatment
with n-3 fatty acid ethyl esters (3 g/d; A) or with
olive oil (3 g/d; B) for 24 weeks. Each point
represents the mean±SEM value for 14 pa-
tients in the n-3 fatty acid group and 15 pa-
tients In the olive oil group at each time, n, •
Indicate unstimulaled monocytes; o, •, endo-
toxin-stimulated monocytes. *Values signifi-
cantly different from corresponding values at
baseline and 12 weeks (P<.05). §Values sig-
nificantly different from corresponding values
of the olive oil group (P<.05).
plasma decreased slightly in the hypertriglyceridemic
patients who received n-3 fatty acids, whereas levels of
18:2 n-6 remained unchanged (Table 3). The 20:4 n-6
to 20:5 n-3 ratio was reduced from 8 at baseline to 1.5
at 24 weeks.
Levels of polyunsaturated fatty acids did not change
in the olive oil group during treatment (levels of 20:5
n-3 were 0.70±0.07% and 0.72±0.08% and of 22:6 n-3
were 1.60±0.12% and 1.74±0.17% of total fatty acids at
baseline and after 24 weeks of treatment, respectively).
Administration of 3 g/d of olive oil did not affect plasma
levels of 18:1 n-9, nor did it influence 18:2 n-6 or 20:4
n-6 levels in plasma.
Discussion
These data indicate that relatively prolonged admin-
istration of a moderate dose of n-3 fatty acids to healthy
subjects and to patients with hypertrigryceridemia re-
duces TF activity in unstimulated and endotoxin-stim-
ulated adherent monocytes.
Data from previous studies on the effects of n-3 fatty
acids on TF activity are conflicting. Inhibition of TF
activity in human mononuclear cells after fish oil ad-
ministration to healthy subjects was previously reported
by Hansen et al.3* This observation, however, was not
confirmed by others.37-38 These latter studies were per-
formed with high doses of n-3 fatty acids (5 g/d)
administered as fish oil for relatively short periods of
time (4 to 8 weeks). Moreover, it has recently been
reported that n-3 fatty acids (5 g/d EPA and DHA)
administered to patients undergoing coronary artery
bypass surgery have no effect or even increase throm-
boplastin generation by monocytes isolated from whole
blood stimulated with endotoxin.39 On the other hand,
administration of 1 g/kg body weight of an n-3 ethyl
ester concentrate to nonhuman primates subjected to
carotid endarterectomy has been shown to result in a
dramatic impairment of mononuclear cell TF activity.24
In the studies cited above, TF activity determination
was performed in a mixed population of lymphocytes
TABLE 3. Fatty Acid Composition of Plasma of Hypertrlglycerldemlc Patients Before, During, and After Treatments
Fatty Adds*
16:0
18:0
16:1
18:1
24:1
18:2n-6
20:3 n-6
20:4 n-6
22:4 n-6
22:5n-6
20:5 n-3
22:5 n-3
22:6 n-3
20:4n-6/20:5n-3
ratio
OWeek
(Baseline)
27.0 ±0.73
6.8±0.2
3.0±0.30
27.6±1.1
0.61 ±0.05
24.5±1.0
1.7±0.41
5.6±0.24
0.32±0.04
0.16±0.05
0.72±0.18
0.41 ±0.07
1.5±0.54
8.7±0.8
n-3 Fatty Add
12 Weeks
26.2±1.18
6.8±0.22
2.7±0.37
23.5±1.1t
0.80±0.06
25.1 ±1.3
1.3±0.08t
5.3±0.27
0.18±0.02t
0.11±0.01t
3.6±0.27t
0.81 ±0.07t
3.7±0.34t
1.6±0.1t
Group (n=14)
18 Weeks
26.2±1.10
7.1 ±0.25
2.4±0.29
24.0±1.1t
0.67±0.05
25.2±1.3
1.3±0.13t
5.2±0.18
0.15±0.01t
0.10±0.01t
3.4±0.23t
0.70±0.04t
3.5±0.19t
1.6±0.1t
24 Weeks
25.0±0.83
7.0±0.18
2.4±0.28
23.2±1.2t
0.85±0.06
25.9±1.4
1.3±0.07t
5.4±0.21
0.17±0.01t
0.11±0.01t
3.7±0.26t
0.89±0.05t
4.1±0.24t
1.5±0.1t
Olive Oil
OWeek
(Baseline)
26.0±1.0
6.6±0.25
2.2±0.20
28.4±1.3
0.53±0.04
26.1±1.3
1.5±0.06
5.5±0.34
0.24±0.02
O.15±0.02
0.70±0.07
0.40±0.03
1.6+0.12
8.8±1.0
Group (n=15)
24 Weeks
24.9±1.0
6.4±0.19
2.1±0.18
26.4±1.2
0.56±0.06
28.9±1.2
1.5±0.09
6.1 ±0.42
0.22±0.03
0.16±0.02
0.72±0.08
0.41 ±0.05
1.7±0.17
9.8±1.3
•Values are percentages of total fatty acids and are expressed as mean±SEM.
"Methods."
tP<-01 versus baseline; n indicates number of patients.
Statistical analysis was performed as described in
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and monocytes. Although lymphocytes do not express
TF activity, it is known that these cells cooperate with
monocytes to amplify TF generation.40 n-3 Fatty acids,
however, are reported to influence several aspects of
lymphocyte function41; thus, the effects of n-3 fatty acids
observed on monocytes might reflect functional changes
at the lymphocyte level. In our study, to assess whether
these fatty acids directly influenced the monocyte, TF
activity was evaluated in a virtually pure population of
adherent monocytes. In addition, to minimize variations
due to adhesion, we normalized the data by expressing
TF activity per microgram of protein. The results indi-
cate that n-3 fatty acids directly impair the capacity of
adherent monocytes to generate TF activity both in the
unstimulated condition and after stimulation with
endotoxin.
In healthy subjects, administration of 3 g/d of n-3
fatty acids (2.5 g/d EPA plus DHA) for periods longer
than 6 weeks suffices to inhibit TF activity in adherent
monocytes. Delay in the onset of effects of n-3 fatty
acids on monocyte TF activity compared with those
observed for other monocyte-derived inflammatory me-
diators, such as cytokines and leukotrienes,9-10 suggests
that TF activity regulation is not an immediate target
for the fatty acids but that they probably act in concert
with other as-yet-unidentified mediators, possibly influ-
encing gene expression. This hypothesis is consistent
with the finding that n-3 fatty acids inhibit gene expres-
sion of platelet-derived growth factor A and B in
monocytes.11 The extent of TF activity inhibition in
unstimulated and endotoxin-stimulated monocytes that
we observed after 12 weeks of treatment with 3 g/d n-3
fatty acids to healthy volunteers was comparable with
that described for mononuclear cells from nonhuman
primates supplemented for 12 weeks with far higher
amounts of n-3 fatty acids. During treatment, inhibition
of TF activity was accompanied by a consistent accumu-
lation of n-3 fatty acids in plasma and monocyte com-
partments. In addition, 20:4 n-6 levels were reduced
during treatment, mostly in monocytes.
Impairment of TF activity persisted after withdrawal
of treatment; plasma and monocyte fatty acid levels
tended to return toward baseline, but the arachidonic
acid to EPA ratio in monocytes still remained signifi-
cantly lower than at baseline. Interestingly, levels of
22:6 n-3 remained consistently high as long as 14 weeks
after treatment withdrawal. It is worth mentioning that
during this study, the subjects did not modify their diet,
nor did they increase their intake of food items contain-
ing n-3 fatty acids. On the other hand, a long-lasting
effect of n-3 fatty acids was previously observed in
platelets42 and monocytes.9 In particular, cytokine syn-
thesis after fish oil administration was shown to be
impaired for more than 10 weeks after stopping
treatment.9
n-3 Fatty acids effectively also reduced TF activity in
hypertriglyceridemic patients, both in unstimulated ad-
herent monocytes and after cell stimulation with endo-
toxin. In hypertriglyceridemic patients, however, TF
activity was reduced to a lesser extent than in normal
subjects. This may be due to the abnormally elevated
levels of triglyceride-rich lipoproteins in hypertriglycer-
idemic plasma that undergo complex interactions with
n-3 fatty acids as well as with the monocyte.43 Inhibition
of TF activity was accompanied by a consistent accumu-
lation of EPA and DHA in the patients' plasma sam-
ples, which was comparable with that observed in
healthy subjects.
TF activity in monocytes isolated from hypertriglyc-
eridemic patients was found to be comparable with that
observed in cells from healthy subjects. Thus, one might
raise the question of the possible significance of atten-
uating TF activity in this pathological condition. Indeed,
as previously discussed, a procoagulant state exists in
hypertriglyceridemia due to elevated amounts of the
essential cofactor for TF activity, ie, factor Vll/VIIa in
plasma.22 Because formation of the TF-VIIa complex is
the first step in triggering the clotting cascade and thus
represents a key regulatory step in controlling activation
of the clotting system, the attenuation of TF activity
following n-3 fatty acid administration may be relevant
to this process.
The molecular mechanism(s) underlying TF activity
reduction after n-3 fatty acid intake is unknown, n-3
Fatty acids, when incorporated into cell membranes, are
substrates for phospholipases and lead to the formation
of prostanoids of the n-3 series, including EPA-derived
leukotrienes and hydroxy fatty acids that possess reduced
biological activities compared with corresponding arachi-
donate-derived products.10 Changes in the capacity of
monocytes to synthesize arachidonate products might
thus influence monocyte TF activity. So far, among
arachidonate-derived products, 12-hydroxyeicosatet-
raenoic acid, the major product of platelet 12-lipoxyge-
nase, has been shown to be implicated in TF activity
regulation.44 The capacity of cells to generate arachidon-
ate products, however, recovers within a short time after
treatment withdrawal and follows the decline of EPA in
cell lipids,10 thus making it unlikely that the impairment
in TF activity that we observed could be ascribed only to
changes in the eicosanoid system. As previously dis-
cussed, n-3 fatty acids are known to impair monocyte
cytokine synthesis. Cytokines induce TF expression in
endothelial cells,45 and interferon gamma and granulo-
cyte-colony stimulating factor act synergistically with
endotoxin to induce macrophage and endothelial cell-
associated TF activity.46-47 Thus, the observed reduction
in monocyte TF activity exerted by n-3 fatty acids asso-
ciated with their long-lasting effect might be ascribed to
modifications in the synthesis of cytokines.
The overall picture of the mechanisms through which
n-3 fatty acids may operate is rendered more complex if
we consider that the effect on TF activity was observed
on adherent monocytes, a condition that triggers several
monocyte functions, including TF activity. Leukocyte
adherence is known to be mediated through expression
of the ft integrin CDllb/CD18, which is involved in
functional enhancement of macrophage TF response.48
Moreover, n-3 fatty acids are known to attenuate leu-
kocyte-endothelium interaction through the increase of
mediators, such as prostacyclin and endothelium-de-
rived-relaxing factor, which negatively influence the
adhesion process.6-49 Further studies, however, are
needed to assess whether the effects of n-3 fatty acids
on monocyte TF activity that we describe here are at
least in part consequent to modifications of the adhesive
machinery of the monocyte.
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In conclusion, the effect of n-3 fatty acids on mono-
cyte TF activity, ie, the reduction in the capacity to
generate thrombin, should be added to other known
activities of these fatty acids that are directed toward an
impairment of monocyte functions. Monocyte-mediated
thrombin generation might occur within the circulation
as well as within the vessel wall in atherosclerotic
plaques. Because our study indicates that n-3 fatty acids
interfere with TF activity induced in monocytes follow-
ing their adhesion, one might speculate that this mech-
anism is operative in the initial formation of atheroscle-
rotic lesions, when the monocyte is the first cell that
adheres to the vascular endothelium.
Thus, n-3 fatty acids that reduce basal and stimulated
TF activity in adherent monocytes may interfere with in
vivo activation of thrombin generation, influencing pos-
itively the prothrombotic risk in hypertrigryceridemic
patients. This hypothesis needs to be further supported
by ad hoc designed clinical studies.
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